ALX Oncology (ALXO) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed ALX Oncology (ALXO) over the past year, gaining 1.5% versus a loss of 25.9%. Over five years, ALXO leads with a -96.8% price change compared with -98.2% for ZNTL. ALX Oncology is the larger company by market cap ($137.0 million vs $133.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | ZNTL |
|---|---|---|
| Share price | $1.06 | $1.36 |
| Market cap | $137.03M | $133.64M |
| 1-day change | +3.92% | 0.00% |
| YTD return | -6.19% | +0.74% |
| 1-year return | -25.87% | +1.49% |
| 5-year return | -96.84% | -98.21% |
| EPS (TTM) | $-0.87 | $-1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-101.69M | $-137.06M |
| 52-week high | $2.66 | $6.95 |
| 52-week low | $0.862 | $1.30 |
| Distance from 52-week high | -60.15% | -80.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +333.96% | +447.06% |
| Average volume | 1.19M | 1.26M |
| Shares outstanding | 129.27M | 98.27M |
| Employees | 49 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed ALXO by 27.4 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
ALXO vs ZNTL FAQ
Which is bigger, ALX Oncology or Zentalis Pharmaceuticals?
ALX Oncology (ALXO) is larger, with a market capitalization of $137.03M compared with $133.64M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, ALXO or ZNTL?
ZNTL returned +1.49% over the past 12 months, compared with -25.87% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.